Next Article in Journal
Phenolic Characterization and Neuroprotective Properties of Grape Pomace Extracts
Previous Article in Journal
Multifunctional Viologen-Derived Supramolecular Network with Photo/Vapochromic and Proton Conduction Properties

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis

Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX 77030, USA
Department of Health Sciences, University of Florence, 50121 Florence, Italy
Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK
Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada Di Fiume 447, 34149 Trieste, Italy
Authors to whom correspondence should be addressed.
Academic Editor: Laura Cerchia
Molecules 2021, 26(20), 6215;
Received: 18 September 2021 / Revised: 9 October 2021 / Accepted: 11 October 2021 / Published: 14 October 2021
Importance: The protein p53 is an unequivocal tumor suppressor that is altered in half of all cancers. The immune system produces systemic p53 autoantibodies (p53 Abs) in many cancer patients. Objective: This systemic review and meta-analysis focuses on the prognostic value of p53 Abs expressed in the serum of patients with solid tumors. Data Sources: All the clinical investigations were searched on PubMed from the first study dated 1993 until May 2021 (date of submission of the manuscript). Study Selection: Studies were included that met the following criteria: (1) participants with cancer; (2) outcome results expressed in relation to the presence of a p53 antibody; (3) a primary outcome (disease-free survival, overall survival or progression-free survival) expressed as hazard ratio (HR). The following exclusion criteria were used: (1) insufficient data available to evaluate outcomes; (2) animal studies; (3) studies with less than 10 participants. As a result, 12 studies were included in the analysis. Data Extraction and Synthesis: PRISMA guidelines were used for abstracting and assessing data quality and validity by three independent observers. The summary estimates were generated using a fixed-effect model (Mantel–Haenszel method) or a random-effect model (DerSimonian–Laird method), depending on the absence or presence of heterogeneity (I2). Main Outcome(s) and Measure(s): The primary study outcome was to determine the prognostic value of p53 Abs from a large population of patients with solid tumors, as determined before data collection. Results: In total, 12 clinical studies involving 2094 patients were included in the meta-analysis, and it was determined that p53 Abs expression in the serum significantly correlated with poorer survival outcomes of cancer patients (95% CI 1.48 [1.24, 1.77]; p < 0.00001). Conclusions and Relevance: This is the first meta-analysis proving the diagnostic utility of p53-Abs for cancer patients in predicting poorer outcomes. The serum-p53 value (s-p53-value) may be useful for future theranostics. View Full-Text
Keywords: meta-analysis; p53; serum p53 antibodies; cancer survival prognostic biomarker meta-analysis; p53; serum p53 antibodies; cancer survival prognostic biomarker
Show Figures

Figure 1

MDPI and ACS Style

Sobhani, N.; Roviello, G.; D’Angelo, A.; Roudi, R.; Neeli, P.K.; Generali, D. p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. Molecules 2021, 26, 6215.

AMA Style

Sobhani N, Roviello G, D’Angelo A, Roudi R, Neeli PK, Generali D. p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. Molecules. 2021; 26(20):6215.

Chicago/Turabian Style

Sobhani, Navid, Giandomenico Roviello, Alberto D’Angelo, Raheleh Roudi, Praveen K. Neeli, and Daniele Generali. 2021. "p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis" Molecules 26, no. 20: 6215.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop